Anadrol and Oxytocin Interaction: Monitor | Peptide Database

Join others researching Noopept — share findings, ask questions, and learn from real experiences Noopept (GVS-111, omberacetam) is a synthetic nootropic dipeptide developed at the Russian Academy of Medical Sciences in the 1990s. It is approved and marketed in Russia and several CIS countries for cognitive impairment of various origins, including post-traumatic and cerebrovascular conditions. Structurally related to the racetam family, Noopept is not technically a racetam itself but is often grouped with them due to a shared mechanism of action involving modulation of glutamatergic neurotransmission. Its standout characteristic is extraordinary potency -- roughly 1000 times more potent than piracetam by weight -- which allows effective dosing in the 10-30 mg range rather than the multi-gram doses required by piracetam. Noopept is rapidly absorbed and converted to its primary active metabolite, cycloprolylglycine, an endogenous neuropeptide that mediates much of the compound's sustained cognitive and neuroprotective activity. Noopept exerts its nootropic and neuroprotective effects through several interconnected mechanisms. It modulates glutamatergic neurotransmission by acting as a positive modulator at AMPA and NMDA receptors, enhancing long-term potentiation (LTP) in the hippocampus -- the core cellular process underlying memory formation. A defining feature of Noopept is its ability to increase the expression of both brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cerebral cortex. BDNF supports synaptic plasticity, neuronal survival, and the growth of new dendritic connections, while NGF is critical for the maintenance and survival of cholinergic neurons in the basal forebrain, a population that degenerates in Alzheimer's disease. Noopept also exhibits antioxidant and anti-inflammatory properties, reducing oxidative stress and inhibiting neurotoxicity induced by excess calcium and glutamate. Additionally, it enhances the activity of inhibitory mechanisms that prevent excitotoxic neuronal damage. After oral administration, Noopept is rapidly metabolized to cycloprolylglycine, which crosses the blood-brain barrier and is thought to mediate much of the compound's longer-lasting neurotrophic activity.

Join others researching Ecdysterone — share findings, ask questions, and learn from real experiences Ecdysterone (20-Hydroxyecdysone) is a naturally occurring phytoecdysteroid -- a class of steroid hormones that regulate molting and metamorphosis in insects and crustaceans. Despite its name and steroidal structure, ecdysterone does not interact with the androgen receptor and operates through an entirely different mechanism than anabolic-androgenic steroids. It is found in meaningful concentrations in common foods such as spinach (Spinacia oleracea), quinoa (Chenopodium quinoa), and various other plants. Ecdysterone gained significant attention in the strength and performance community following a 2019 study from Freie Universitat Berlin, which demonstrated that trained individuals supplementing with ecdysterone experienced significantly greater muscle mass gains compared to placebo over a 10-week resistance training program. The effect sizes were large enough that the study authors themselves recommended the World Anti-Doping Agency (WADA) consider adding ecdysterone to the prohibited substances list. Unlike traditional anabolic agents, ecdysterone does not cause hormonal suppression, does not require post-cycle therapy, and carries an exceptionally mild side effect profile. Its mechanism appears to involve signaling through estrogen receptor beta (ERbeta), which activates anabolic pathways in skeletal muscle without the androgenic, estrogenic, or hepatotoxic effects associated with traditional performance-enhancing compounds. An injectable form has gained popularity among advanced users seeking higher bioavailability, as oral ecdysterone suffers from significant first-pass metabolism. Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling. ERbeta is expressed in skeletal muscle tissue, and its activation triggers downstream anabolic signaling cascades including the PI3K/Akt pathway, which promotes muscle protein synthesis and inhibits protein degradation. This pathway converges on mTOR (mechanistic target of rapamycin), a master regulator of muscle hypertrophy, leading to increased translation of muscle-specific proteins. Importantly, ecdysterone does not activate estrogen receptor alpha (ERalpha), which is responsible for the feminizing effects of estrogens, nor does it bind to the androgen receptor, glucocorticoid receptor, or mineralocorticoid receptor. This selectivity explains why ecdysterone does not produce the hormonal side effects associated with anabolic steroids -- there is no testosterone suppression, no testicular atrophy, no gynecomastia, no liver toxicity, and no virilization in women. Additional proposed mechanisms include enhanced nitrogen retention in muscle tissue, improved calcium handling in muscle fibers leading to better contractile efficiency, and mild anti-inflammatory effects that may support recovery from exercise-induced muscle damage. Some in vitro studies also suggest ecdysterone may increase satellite cell proliferation, which could contribute to long-term muscle growth capacity.